Literature DB >> 16187277

Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung.

Shinichi Toyooka, Yasushi Yatabe, Masaki Tokumo, Kouichi Ichimura, Hiroaki Asano, Kunitoshi Tomii, Motoi Aoe, Hiroyuki Yanai, Hiroshi Date, Tetsuya Mitsudomi, Nobuyoshi Shimizu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16187277     DOI： 10.1002/ijc.21500

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  25 in total

1.  Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.

Authors:  Zhengbo Song; Xinmin Yu; Yiping Zhang
Journal:  Cancer Biol Ther       Date:  2016-09-16       Impact factor: 4.742

2.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

3.  Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

Authors:  Paul K Paik; Anna M Varghese; Camelia S Sima; Andre L Moreira; Marc Ladanyi; Mark G Kris; Natasha Rekhtman
Journal:  Mol Cancer Ther       Date:  2012-08-14       Impact factor: 6.261

Review 4.  Role of genotyping in non-small cell lung cancer treatment: current status.

Authors:  Laura Bonanno; Adolfo Favaretto; Massimo Rugge; Miquel Taron; Rafael Rosell
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

5.  An early event of EGFR mutation in pleomorphic carcinoma of the lung.

Authors:  Miyako Saitoh; Mafumi Niijima; Yuichi Takiguchi; Kenzo Hiroshima; Yoshihiko Fujita; Kazuto Nishio; Koichiro Tatsumi
Journal:  Int J Clin Oncol       Date:  2011-05-11       Impact factor: 3.402

6.  Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Authors:  Natasha Rekhtman; Paul K Paik; Maria E Arcila; Laura J Tafe; Geoffrey R Oxnard; Andre L Moreira; William D Travis; Maureen F Zakowski; Mark G Kris; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2012-01-06       Impact factor: 12.531

Review 7.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

8.  Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in non-adenocarcinoma lung cancer patients.

Authors:  Hideaki Yashima; Kimihiro Shimizu; Takuya Araki; Tohru Aomori; Yoichi Ohtaki; Toshiteru Nagashima; Yasuaki Enokida; Jun Atsumi; Tomonori Nakamura; Izumi Takeyoshi; Koujirou Yamamoto
Journal:  Mol Clin Oncol       Date:  2014-06-03

9.  Clinicopathological features and surgical outcomes of adenosquamous carcinoma of the pancreas: a retrospective analysis of patients with resectable stage tumors.

Authors:  Hirotake Komatsu; Shinichi Egawa; Fuyuhiko Motoi; Takanori Morikawa; Naoaki Sakata; Takeshi Naitoh; Yu Katayose; Kazuyuki Ishida; Michiaki Unno
Journal:  Surg Today       Date:  2014-06-29       Impact factor: 2.549

10.  Adenosquamous cell lung cancer successfully treated with gefitinib: A case report.

Authors:  Koichi Kurishima; Gen Ohara; Katsunori Kagohashi; Hiroko Watanabe; Norio Takayashiki; Atsushi Ishibashi; Hiroaki Satoh
Journal:  Mol Clin Oncol       Date:  2013-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.